drugset / Trial / NCT02836418

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT02836418 ↗

Phase 1/2 Completed 8 enrolled aTyr Pharma, Inc.
NaSingle-groupOpen-labelTreatment

Summary

ATYR1940-C-006 is a multi-national, multicenter study being conducted at centers in the United States (US) and Europe who participated in Study ATYR1940-C-003 (Stage 1 only) or Study ATYR1940-C-004 (that is, the parent studies).

Timeline

Start
2016-07-13
Primary completion
2017-04-18
Completion
2017-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject ATYR1940 Unknown 3 mg/kg Intravenous